This study is an open-label feasibility study with definitive clinical endpoints of insulin independence, blood glucose and C peptide production as measures of procedural success. As donor islets become available the appropriate ABO compatible blood types will be matched to eligible participants. Clinical investigators are not masked to treatment assignment or follow up assessment information for this pilot study.